The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee recently discussed the increased risk of Andexxa clotting-related deaths and Andexxa blood clots seen in the ANNEXA-I trial done for Andexxa, compared with a standard of care reversal agent. This Andexxa Advisory Committee considered the current drug safety profile of Andexxa in … [Read more...]
Depo-Provera Meningioma Brain Tumors Drug Injury Lawsuits
Because the current drug label for Depo-Provera Contraceptive Injection (version “Revised: 7/2024”, accessed 10/16/24) does not include any warning about an increased risk of intracranial meningioma, we are investigating possible Depo-Provera meningioma brain tumors drug injury lawsuits seeking legal compensation for women who have been diagnosed … [Read more...]
No Federal Preemption for Fosamax MDL Femur Fracture Lawsuits: September 2024 Update
The United States Court of Appeals for the Third Circuit recently issued this opinion, In re: Fosamax (alendronate sodium) Products Liability Litigation, No. 22-3412, (3d Cir. Sept. 20, 2024), ruling that there is no federal preemption for more than 500 Fosamax MDL femur fracture lawsuits that had been dismissed previously and therefore, should now … [Read more...]
Menopause Drug Veozah Liver Problems FDA Warnings
A Veozah drug label change made on August 31, 2024, added new warnings about liver toxicity and abnormal liver test results, according to a September 12, 2024, Veozah liver problems FDA Drug Safety Communication. According to the “Additional Information for Patients” section of the September 2024 FDA Veozah liver problems warnings document, … [Read more...]
Syfovre Claims: Vision Loss and Blindness: Law / Legal
Syfovre claims for vision loss and blindness involving retinal vasculitis diagnosed after a patient’s first Syfovre injection are being filed as drug injury lawsuits. The basis for these product liability Syfovre lawsuits is the drug company Apellis Pharmaceuticals failed to warn about retinal vasculitis as a side effect until it revised the … [Read more...]
Semaglutide Blood Clots Side Effects: Ozempic, Rybelsus, and Wegovy
We have been receiving reports of people diagnosed with deep vein thrombosis (DVT), pulmonary embolism (PE), portal vein thrombosis (PVT), and ischemic stroke as possible semaglutide blood clots side effects. Ozempic, Rybelsus, and Wegovy are drugs with semaglutide as their active ingredient. Semaglutide Blood Clots Side Effects: DVT and Pulmonary … [Read more...]
Ozempic Side Effects Include Eye Problems With Possible Vision Loss
In July 2024 we learned from a recent medical study that Ozempic side effects include eye problems with possible vision loss. More specifically, nonarteritic anterior ischemic optic neuropathy (NAION) has been linked to semaglutide — the active ingredient in Ozempic as well as Wegovy and Rybelsus. As such, this finding about the new NAION Ozempic … [Read more...]
Syfovre’s Side Effects Keep It Off The Market In Europe (CHMP June 2024)
As we have been reporting since July 2023, Syfovre’s side effects include occlusive retinal vasculitis, a type of eye inflammation that blocks blood flow to the retina resulting in vision loss and potentially causing blindness. There have also been cases of non-occlusive retinal vasculitis and other types of eye inflammation. In late June 2024, … [Read more...]
Blood Clots When Using Wegovy, Rybelsus, or Ozempic
Drug injury lawsuits that might be filed against the pharmaceutical company Novo Nordisk involving blood clots when using Wegovy, Rybelsus, or Ozempic are somewhat like the federal court Wegovy/Rybelsus/Ozempic MDL lawsuits involving gastrointestinal and stomach problems because they would involve similar — but different — liability issues, such … [Read more...]
Syfovre: Eye Problems After Injection of Syfovre (pegcetacoplan)
This blog post is about a 78-year-old woman with Syfovre eye problems involving vision loss in the first part of 2023. This Syfovre side effects case was reported in “Retinal vasculitis following intravitreal pegcetacoplan administration”, a medical journal article that appeared in the March 2024 edition of the American Journal of Ophthalmology … [Read more...]
- 1
- 2
- 3
- …
- 7
- Next Page »